Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 11/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | TARS1 | P26639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605513 | 0.87 | DHFR (1.00) | DHFRMAP4K4DCPSHRH4TARS1 | |
| SCHEMBL5507908 | 0.86 | DHFR (0.75) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL13888558 | 0.84 | DHFR (0.93) | DHFRMAP4K4DCPSHRH4TARS1 | |
| SCHEMBL6094113 | 0.84 | DHFR (0.72) | DHFRMAP4K4DCPS | |
| SCHEMBL15587285 | 0.78 | MAP4K4 (1.00) | DHFRMAP4K4 | |
| SCHEMBL4510941 | 0.76 | DHFR (0.64) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL8512311 | 0.76 | DHFR (1.00) | DHFRMAP4K4DCPSHRH4 | |
| SCHEMBL4532538 | 0.75 | DHFR (0.62) | DHFRMAP4K4DCPSHRH4TARS1 | |
| SCHEMBL8509095 | 0.75 | DHFR (1.00) | DHFR | |
| SCHEMBL4529864 | 0.75 | DHFR (0.62) | DHFRMAP4K4DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835445-B2 | Dihydrofolate reductase inhibitors | TRIUS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835445-B2 | Dihydrofolate reductase inhibitors | TRIUS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835445-B2 | Dihydrofolate reductase inhibitors | TRIUS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | DHFR, DPYD, DHODH | DHFR 1/4885MAP4K4 4343/4885DCPS 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.